The addition of veliparib to adjuvant temozolomide failed to improve OS for patients with newly diagnosed, MGMT-hypermethylated glioblastoma, according to randomized phase 2/phase3 study results.Patients assigned the investigative combination achieved a 3.3-month improvement in median OS; however, the difference did not reach statistical significance.
Asciminib continued to improve outcomes when compared to investigator-selected TKIs in patients with newly diagnosed, Ph+ CML-CP in the ASC4FIRST trial.
A calorie deficit occurs when you burn more calories than you consume, says senior clinical dietitian Jessica Tilton. Here, she explains how physical activity and…
Here we present a visual abstract of a retrospective study by Decaux et al. which evaluated real-world outcomes following at least one dose of Isa-Pd…
The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients with pretreated advanced urothelial carcinoma.
Register for Exploring a New Generation of Patient-Centric Cancer Clinical Trials, a virtual patient advocacy event hosted by the AACR.
The Paris System for Reporting Urinary Cytology (TPS) requires at least 5–10 malignant cells to diagnose HGUC in lower and upper urinary tract specimens, respectively,…
Basch, an oncologist and researcher who moonlights as a bass player, is in tune with colleagues and patients.
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
The NCCN guidelines have stated that osimertinib is the preferred category 1 treatment for patients with EGFR-mutated NSCLC discovered before the first line of therapy.
NCCN is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education, is dedicated to improving and facilitating quality, effective,…
